Monthly Prescribing Reference

Tremfya SC Induction Regimen Approved for Adults With Ulcerative Colitis

Findings at week 12 showed a significantly greater proportion of patients treated with the SC induction regimen achieved clinical remission compared with those who received placebo. The Food and Drug ...
Monthly Prescribing Reference

Study Supports Guselkumab SC Induction Regimen in Patients With Ulcerative Colitis

Findings showed a significantly greater proportion of patients treated with the SC induction regimen achieved clinical remission, clinical response, and endoscopic improvement compared with placebo.
Nasdaq

Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor

Following recent U.S. FDA approval of TREMFYA® for adults with moderately to severely active ulcerative colitis (UC), this submission underscores its potential to be the only IL-23 inhibitor that ...
Hosted on MSN

FDA Approves Johnson & Johnson’s Tremfya Subcutaneous Induction for Ulcerative Colitis

HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved a subcutaneous induction regimen of TREMFYA (guselkumab) for the treatment of adults with ...
Seeking Alpha

TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen

TREMFYA ® offers the flexibility of self-administration from the start of treatment, building on the prior approval of subcutaneous induction in Crohn's disease TREMFYA ® achieved significant rates of ...
Nasdaq

J&J Seeks FDA Nod for Subcutaneous Tremfya as Induction Regimen in UC

Johnson & Johnson JNJ announced that it has submitted a regulatory filing with the FDA seeking approval for the use of a subcutaneous (SC) induction regimen of its blockbuster immunology medicine ...
clinicaladvisor.com

FDA Approves Subcutaneous Tremfya Induction Treatment for Ulcerative Colitis

Compared with placebo, significantly greater proportions of patients treated with Tremfya achieved clinical remission and endoscopic improvement. HealthDay News — The US Food and Drug Administration ...